BCM
INBX icon

Bridgeway Capital Management’s Inhibrx INBX Stock Holding History

Bridgeway Capital Management’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$437K Sell
6,500
-2,500
-28% -$185K 0.01% 845
2025
Q4 		$711K Sell
9,000
-7,500
-45% -$511K 0.01% 760
2025
Q3 		$556K Hold
16,500
– – 0.01% 783
2025
Q2 		$235K Buy
+16,500
New +$213K 0.01% 923

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bridgeway Capital Management's INBX Position: Q1 2026 in Review

Bridgeway Capital Management reduced its Inhibrx (INBX) stake by 28% in Q1 2026, selling an estimated $185K and leaving 6,500 shares worth $437K. The position accounts for 0.01% of the portfolio, ranked #845.

Bridgeway Capital Management first reported a position in INBX in Q2 2025 and has held it in 4 quarters since. The position peaked at $711K in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Bridgeway Capital Management held 6,500 shares of Inhibrx worth $437K as of Q1 2026.
  • Bridgeway Capital Management sold 2,500 Inhibrx shares in Q1 2026, an estimated $185K.
  • Inhibrx made up 0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #845 holding.
  • Bridgeway Capital Management first reported a position in Inhibrx in Q2 2025 and has held it in 4 quarters since.
  • Bridgeway Capital Management's Inhibrx position peaked at $711K in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.